vs
Side-by-side financial comparison of Fatpipe Inc (FATN) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $4.1M, roughly 1.6× Fatpipe Inc). Fatpipe Inc runs the higher net margin — 7.6% vs -303.5%, a 311.1% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs 3.2%).
FATN vs PRLD — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $6.5M |
| Net Profit | $310.7K | $-19.7M |
| Gross Margin | 87.7% | — |
| Operating Margin | 9.8% | -314.1% |
| Net Margin | 7.6% | -303.5% |
| Revenue YoY | 3.2% | 116.7% |
| Net Profit YoY | 816.0% | 38.9% |
| EPS (diluted) | $0.02 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | — | ||
| Q3 25 | $4.0M | $6.5M | ||
| Q2 25 | $3.9M | — | ||
| Q3 24 | — | $3.0M |
| Q4 25 | $310.7K | — | ||
| Q3 25 | $-43.4K | $-19.7M | ||
| Q2 25 | $741.2K | — | ||
| Q3 24 | — | $-32.3M |
| Q4 25 | 87.7% | — | ||
| Q3 25 | 92.1% | — | ||
| Q2 25 | 94.2% | — | ||
| Q3 24 | — | — |
| Q4 25 | 9.8% | — | ||
| Q3 25 | -0.0% | -314.1% | ||
| Q2 25 | 25.5% | — | ||
| Q3 24 | — | -1145.9% |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -1.1% | -303.5% | ||
| Q2 25 | 18.8% | — | ||
| Q3 24 | — | -1075.7% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $0.00 | $-0.26 | ||
| Q2 25 | $0.05 | — | ||
| Q3 24 | — | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.0M |
| Total DebtLower is stronger | $4.6M | — |
| Stockholders' EquityBook value | $21.2M | $58.5M |
| Total Assets | $32.4M | $94.8M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $55.0M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $153.6M |
| Q4 25 | $4.6M | — | ||
| Q3 25 | $4.8M | — | ||
| Q2 25 | $4.9M | — | ||
| Q3 24 | — | — |
| Q4 25 | $21.2M | — | ||
| Q3 25 | $21.0M | $58.5M | ||
| Q2 25 | $20.4M | — | ||
| Q3 24 | — | $156.4M |
| Q4 25 | $32.4M | — | ||
| Q3 25 | $32.2M | $94.8M | ||
| Q2 25 | $32.0M | — | ||
| Q3 24 | — | $197.2M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.24× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $240.9K | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $240.9K | — | ||
| Q3 25 | $399.8K | $-19.1M | ||
| Q2 25 | $-508.6K | — | ||
| Q3 24 | — | $-27.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-551.1K | — | ||
| Q3 24 | — | $-27.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -14.0% | — | ||
| Q3 24 | — | -912.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 1.1% | — | ||
| Q3 24 | — | 2.1% |
| Q4 25 | 0.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.69× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FATN
| Products | $2.6M | 63% |
| Other | $1.5M | 37% |
PRLD
Segment breakdown not available.
